PPD Inc

PPD — Debt Investor Presentation (February 2020)

9 slides from PPD's debt investor presentation, Feb 18, 2020

  1. Slide 1: Lender Presentation

    Slide 1: Lender Presentation

    Lender Presentation* * Select pages Exhibit 99.1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements, which are subject to risks, uncertainties and assumptions about PPD, Inc. “the (“Company”), may include projections of the Company’s future financial

  3. Slide 3: Executive summary

    Slide 3: Executive summary

    Executive summary PPD, Inc. (“PPD” or the “Company”) is a leading global contract research organization (“CRO”) and has been in the drug development business for more than 30 years For the FYE 12/31/19E, PPD expects Segment Revenues1 and Adjusted EBITDA of $3,140 million2 and $775 million2, respecti

  4. Slide 4: Summary of Indicative Terms

    Slide 4: Summary of Indicative Terms

    Summary of Indicative Terms Borrower: PPD, Inc. (“PPD” or the “Borrower”) Co-Borrower: PPD Development, L.P. (“PPDLP” or the “Co-Borrower”) Guarantors: All direct and indirect wholly owned domestic subsidiaries of the Company, subject to agreed upon exceptions, Wildcat Acquisition Holdings (UK) Limi

  5. Slide 5: Pro forma capitalization

    Slide 5: Pro forma capitalization

    Pre-IPO 12/31/20E Step 1: PF IPO Step 2: PF full refi 12/31/19E ($mm) Amount xEBITDA Rate Maturity Call price ∆ Amount xEBITDA ∆ Amount xEBITDA Maturity Cash & equivalents $344 277 $621 (211) $410 Revolving Credit Facility - L + 325 Aug-20 - - - - 5 years Existing 1st lien Term Loan B 3,096 L + 250

  6. Slide 6: Revenue Reconciliation

    Slide 6: Revenue Reconciliation

    Revenue Reconciliation 1 Other Revenue represents third-party pass-through and out of pocket revenue, and the impact from revenue recognition methods under ASC 606 as compared to ASC 605 2 Total Revenue represented on an ASC 605 basis from 2015 to 2018; on an ASC 606 basis for 2019E 3 Represents Seg

  7. Slide 7: Unlevered Free Cash Flow Reconciliation

    Slide 7: Unlevered Free Cash Flow Reconciliation

    1 Financials represented on an ASC 605 basis from 2015 to 2018; on an ASC 606 basis for 2019E 2 See other appendix slide for reconciliation of Adjusted EBITDA 3 Conversion % calculated as unlevered free cash flow divided by Adjusted EBITDA Unlevered Free Cash Flow Reconciliation1 ASC605 ASC606

  8. Slide 8: Adjusted EBITDA and Adjusted EBITDA Margin Reconciliation

    Slide 8: Adjusted EBITDA and Adjusted EBITDA Margin Reconciliation

    Adjusted EBITDA and Adjusted EBITDA Margin Reconciliation1,2 1 EBITDA reconciliation presented on an ASC 605 basis for 2015 to 2018 and an ASC 606 basis for 2019E 2 Adjusted EBITDA margin for 2015 – 2018 (ASC 605) defined as (a) Adjusted EBITDA divided by (b) Segment Revenues (excluding third-party

  9. Slide 9: Adjusted EBITDA adjustment footnotes

    Slide 9: Adjusted EBITDA adjustment footnotes

    Represents the Company’s costs associated with special cash bonuses paid to the Company’s option holders. Represents management fees incurred under consulting services agreements with our Majority Sponsors. These consulting services agreements terminated with the IPO. Represents employee separation

Source: SEC EDGAR · 8-K filed Feb 18, 2020